HEPION PHARMACEUTICALS, INC. Amortization of Debt Discount (Premium)
HEPION PHARMACEUTICALS, INC. (HEPA) reported Amortization of Debt Discount (Premium) of $1.27 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-12
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $794.25K.
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2019-12-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2019-09-30 was -$4.00.
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2019-06-30 was $417.10K.
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for fiscal 2024 was $1.27M.
- HEPION PHARMACEUTICALS, INC. amortization of debt discount (premium) for fiscal 2019 was $486.61K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $794.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.27M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $474.57K 10-Q · filed 2025-11-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$4.00 derived: sum of 2 quarters · filed 2021-03-31 | $417.09K derived: sum of 3 quarters · filed 2021-03-31 | $486.61K 10-K · filed 2021-03-31 |
| 2019-09-30 | -$4.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $417.09K derived: sum of 2 quarters · filed 2020-11-16 | $486.61K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $417.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $486.61K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $69.52K 10-Q · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |